We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Food and Drug Administration (FDA) is down-classifying ovarian adnexal mass assessment score test systems from Class III into Class II with special controls.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor